CoChat

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

The DOI matches its Crossref record; 59 of the 63 references it cites were found in a registry or an index.

Abstract

Background The frequency of obesity has risen dramatically in recent years but only few safe and effective drugs are currently available. We assessed the effect of liraglutide on bodyweight and tolerability in obese individuals without type 2 diabetes. Methods We did a double-blind, placebo-controlled 20-week trial, with open-label orlistat comparator in 19 sites in Europe. 564 individuals (18-65 years of age, body-mass index 30-40 kg/m2) were randomly assigned, with a telephone or web-based system, to one of four liraglutide doses (1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg, n=90-95) or to placebo (n=98) administered once a day subcutaneously, or orlistat (120 mg, n=95) three times a day orally. All individuals had a 500 kcal per day energy-deficit diet and increased their physical activity throughout the trial, including the 2-week run-in. Weight change analysed by intention to treat was the primary endpoint. An 84-week open-label extension followed. This study is registered with ClinicalTrials.gov, number NCT00422058. Findings Participants on liraglutide lost significantly more weight than did those on placebo (p=0.003 for liraglutide 1.2 mg and p Interpretation Liraglutide treatment over 20 weeks is well tolerated, induces weight loss, improves certain obesity-related risk factors, and reduces prediabetes. Funding Novo Nordisk A/S, Bagsvaerd, Denmark.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(09)61375-1

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 59 references

Research works printed but not linked: 2

  1. 2003, US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, JAMA, 289, 2560
  2. Garber, 2009, Monotherapy with liraglutide, a once-daily human GLP-1 analog, provides sustained reductions in A1c, FPG, and weight compared with glimepiride in type 2 diabetes: LEAD-3 mono 2-year results, Diabetes, 58, A42

Cited by

See all 1,163

Metadata

Authors
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E.
Affiliations
  • University of Copenhagen (DK)
  • Karolinska University Hospital (SE)
  • Helsinki University Hospital (FI)
  • Kuopio University Hospital (FI)
  • Novo Nordisk (Denmark) (DK)
  • Glasgow Royal Infirmary (GB)
Venue
The Lancet
Publisher
Elsevier BV
Published
2009-11
Volume
374
Issue
9701
Pages
1606-1616
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2152835319
Cited by
1,163
References
63
Citations by year
2026: 36 · 2025: 56 · 2024: 101 · 2023: 75 · 2022: 63 · 2021: 59 · 2020: 42 · 2019: 47 · 2018: 43 · 2017: 54 · 2016: 68 · 2015: 96 · 2014: 90 · 2013: 94 · 2012: 75
FWCI
56.74
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
liraglutide, obesity, weight loss, GLP-1 receptor agonists, orlistat, body weight, tolerability, adverse events, energy deficit diet, physical activity, dose-response relationship, subcutaneous administration, non-diabetic obesity, open-label extension, weight regain, weight regain prevention, weight loss maintenance
MeSH terms
Liraglutide, Orlistat, Analysis of Variance, Dose-Response Relationship, Drug, Double-Blind Method, Europe, Female, Humans, Injections, Subcutaneous, Lactones, Male, Obesity, Prediabetic State, Safety, Weight Loss, Body Mass Index, Logistic Models, Treatment Outcome, Anti-Obesity Agents, Glucagon-Like Peptide 1, Waist Circumference

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. https://app.cochat.ai/papers/10.1016/s0140-6736(09)61375-1
The paper
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009). Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. The Lancet. https://doi.org/10.1016/s0140-6736(09)61375-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.